SCOPUS 정보 검색 플랫폼

Volumn 7, Issue 3, 2001, Pages 486-492

A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma

(8) Atkins, Michael B a Mier, James a Gollob, Jared a Redman, Bruce b Weber, Jeffrey c Sosman, Jeffrey d Macpherson, Bret L e Plasse, Terry e

a BETH ISRAEL DEACONESS MEDICAL CENTER (United States)

b UNIVERSITY OF MICHIGAN HEALTH SYSTEM (United States)

c UNIVERSITY OF SOUTHERN CALIFORNIA (United States)

d UNIVERSITY OF ILLINOIS AT CHICAGO (United States)

e Cytokine PharmaSciences (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOKINE; INDOMETACIN; INTERLEUKIN 2; PARACETAMOL; RANITIDINE; SEMAPIMOD; TUMOR NECROSIS FACTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HYPOTENSION; KIDNEY CANCER; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COHORT STUDIES; CREATININE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDRAZONES; INTERLEUKIN-2; KIDNEY; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034900743 PISSN: 10780432 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (49)

References (31)

1
- 0021837706
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
- (1985) J. Exp. Med. , vol.161 , pp. 1169-1188
- Rosenberg, S.A.¹ Mule, J.J.² Spiess, P.J.³ Reichert, C.M.⁴ Schwarz, S.L.⁵

2
- 0028266553
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
- (1994) J. Am. Med. Assoc. , vol.271 , pp. 907-913
- Rosenberg, S.A.¹ Yang, J.C.² Topalian, S.L.³ Schwartzentruber, D.J.⁴ Weber, J.S.⁵ Parkinson, D.R.⁶ Seipp, C.A.⁷ Einhorn, J.H.⁸ White, D.E.⁹

3
- 0028929682
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
- (1995) J. Clin. Oncol. , vol.13 , pp. 688-696
- Fyfe, G.¹ Fisher, R.I.² Rosenberg, S.A.³ Sznol, M.⁴ Parkinson, D.R.⁵ Louie, A.C.⁶

4
- 0031812910
- Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
- (1998) Cancer (Phila.) , vol.83 , pp. 797-805
- Kammula, U.S.¹ White, D.E.² Rosenberg, S.A.³

5
- 0028147594
- Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma
- (1994) Oncology , vol.51 , pp. 59-62
- Lissoni, P.¹ Barni, S.² Ardizzoia, A.³ Crispino, S.⁴ Paolorossi, F.⁵ Andres, M.⁶ Scardino, E.⁷ Tancini, G.⁸

6
- 0028106484
- Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
- (1994) J. Clin. Oncol. , vol.12 , pp. 1572-1576
- Yang, J.C.¹ Topalian, S.L.² Parkinson, D.³ Schwartzentruber, D.J.⁴ Weber, J.S.⁵ Ettinghausen, S.E.⁶ White, D.E.⁷ Steinberg, S.M.⁸ Cole, D.J.⁹ Kim, H.I.¹⁰

7
- 0027199879
- Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: An outpatient multicenter trial
- (1993) J. Clin. Oncol. , vol.11 , pp. 1809-1816
- Vogelzang, N.J.¹ Lipton, A.² Figlin, R.³

8
- 0000200416
- IL-2-based therapy in metastatic renal cancer (MRCC): Cytokine working group (CWG) experience
- (1997) Proc. Am. Soc. Clin. Oncol. , vol.16 , pp. 327
- Dutcher, J.¹ Atkins, M.² Fisher, R.³ Weiss, G.⁴ Margolin, K.⁵ Aronson, F.⁶ Lotze, M.⁷ Gordon, M.⁸

9
- 0024266636
- IL-2 stimulates the production of IL-1 α and IL-1 β by human peripheral blood mononuclear cells
- (1988) J. Immunol. , vol.141 , pp. 4250-4257
- Numerof, R.P.¹ Aronson, F.R.² Mier, J.W.³

10
- 0024231234
- Induction of circulating tumor necrosis factor (TNF α) as the mechanism for febrile response to interleukin-2 (IL-2) in cancer patients
- (1988) J. Clin. Immunol. , vol.8 , pp. 426-436
- Mier, J.W.¹ Vachino, G.² Van der Meer, J.W.M.³ Numerof, R.P.⁴ Adams, S.⁵ Cannon, J.G.⁶ Bernheim, H.A.⁷ Atkins, M.B.⁸ Parkinson, O.R.⁹ Dinerello, C.A.¹⁰

11
- 0023707073
- Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells
- (1988) Cancer Res. , vol.48 , pp. 5864-5871
- Gemlo, B.T.¹ Palladino, M.A.² Jaffe, H.S.³ Espevik, T.P.⁴ Rayner, A.A.⁵

12
- 0024400770
- Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients
- (1989) J. Immunol. , vol.143 , pp. 736-739
- Kasid, A.¹ Director, E.P.² Rosenberg, S.A.³

13
- 0024441944
- In vivo induction of γ interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous bone marrow transplantation
- (1989) Blood , vol.74 , pp. 1374-1380
- Heslop, H.E.¹ Gottlieb, D.J.² Bianchi, A.C.³ Meager, A.⁴ Prentice, H.G.⁵ Mehta, A.B.⁶ Hoffbrand, A.V.⁷ Brenner, M.K.⁸

14
- 0026605238
- Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy
- (1992) J. Clin. Investig. , vol.89 , pp. 867-877
- Hibbs, J.B.¹ Westenfelder, C.² Taintor, R.³ Vavrin, Z.⁴ Kablitz, C.⁵ Baranowski, R.L.⁶ Ward, J.H.⁷ Menlove, R.L.⁸ McMurry, M.P.⁹ Kushner, J.P.¹⁰

15
- 0026684595
- Increased circulating nitrogen oxides after human tumor immunotherapy: Correlation with toxic hemodynamic changes
- (1992) J. Natl. Cancer Inst. , vol.84 , pp. 864-867
- Ochoa, J.B.¹ Curti, B.² Peitzman, A.B.³ Simmons, R.L.⁴ Billiar, T.R.⁵ Hoffman, R.⁶ Rault, R.⁷ Longo, D.L.⁸ Urba, W.J.⁹ Ochoa, A.C.¹⁰

16
- 15844399881
- Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone
- (1996) J. Exp. Med. , vol.83 , pp. 927-936
- Bianchi, M.¹ Bloom, O.² Raabe, T.³ Cohen, P.S.⁴ Chesney, J.⁵ Sherry, B.⁶ Schmidtmayerova, H.⁷ Calandra, T.⁸ Zhang, X.⁹ Bukrinsky, M.¹⁰

17
- 0030831395
- Small molecule inhibition of tumor necrosis factor gene processing during acute pancreatitis prevents cytokine cascade progression and attenuates pancreatitis severity
- (1997) Am. Surg. , vol.63 , pp. 1045-1049
- Denham, W.¹ Fink, G.² Yang, J.³ Ulrich, P.⁴ Tracey, K.⁵ Norman, J.⁶

18
- 0032103940
- Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent
- (1998) J. Immunol. , vol.160 , pp. 5588-5595
- Martiney, J.¹ Rajan, A.J.² Charles, P.C.³ Cerami, A.⁴ Ulrich, P.C.⁵ Macphail, S.⁶ Tracey, K.J.⁷ Brosnan, C.F.⁸

19
- 0000935929
- A novel inhibitor of inflammatory cytokine production (CNI-1493) is cerebro-protective in permanent focal cerebral ischemia
- (1997) Surg. Forum , vol.47 , pp. 568-570
- Cockroft, K.M.¹ Meistrell, M.² Ulrich, P.³

20
- 0032516008
- The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor activity
- (1998) Proc. Natl. Acad. Sci. USA , vol.95 , pp. 4561-4566
- Kemeny, M.M.¹ Botchkina, G.I.² Ochani, M.³ Bianchi, M.⁴ Urmacher, C.⁵ Tracey, K.J.⁶

21
- 0024514149
- Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines
- (1989) J. Clin. Oncol. , vol.7 , pp. 486-498
- Margolin, K.A.¹ Rayner, A.A.² Hawkins, M.J.³ Atkins, M.B.⁴ Dutcher, J.P.⁵ Fisher, R.I.⁶ Weiss, G.R.⁷ Doroshow, J.H.⁸ Jaffe, H.S.⁹ Roper, M.¹⁰

22
- 0003656150
- Chapter 2, New York: John Wiley Sons, Inc.
- (1981) Applied Regression Analysis, Ed. 2 , pp. 20-140
- Draper, N.¹ Smith, H.²

23
- 0000722192
- Chapter 11, New York: Marcel Dekker, Inc.
- (1982) Pharmacokinetics Ed. 2 , pp. 409-417
- Gibaldi, M.¹ Perrier, D.²

24
- 0026475205
- Clinical toxicity of interleukin-2
- (1992) Drug Saf. , vol.7 , pp. 417-433
- Vial, T.¹ Descotes, J.²

25
- 4243670414
- February
- (1998) Proleukin package insert

26
- 0033620643
- Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
- (1999) Am. J. Med. , vol.106 , pp. 13-24
- Whelton, A.¹

27
- 0027478126
- Renal toxicity of the nonsteroidal anti-inflammatory drugs
- (1993) Ann. Rev. Pharmacol. Toxicol. , vol.33 , pp. 435-465
- Murray, M.D.¹ Brater, D.C.²

28
- 0024848730
- Interaction and selection of therapeutic agents in the elderly
- (1989) Scand. J. Rheumatol. , vol.82 , pp. 33-38
- Stillman, M.T.¹

29
- 0031043250
- Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma
- (1997) J. Clin. Oncol. , vol.15 , pp. 1052-1062
- Du Bois, J.S.¹ Trehu, E.G.² Mier, J.W.³ Shapiro, L.⁴ Epstein, M.⁵ Klempner, M.⁶ Dinarello, C.⁷ Kappler, K.⁸ Ronayne, L.⁹ Rand, W.¹⁰ Atkins, M.B.¹¹

30
- 0033574147
- Etanercept therapy in rheumatoid arthritis
- (1999) Ann. Intern. Med. , vol.130 , pp. 478-486
- Moreland, L.W.¹ Schiff, M.H.² Baumgartner, S.W.³ Tindall, E.A.⁴ Fleischmann, R.M.⁵ Bulpitt, K.J.⁶ Weaver, A.L.⁷ Keystone, E.C.⁸ Furst, D.E.⁹ Mease, P.J.¹⁰

31
- 0033614816
- Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
- (1999) Circulation , vol.99 , pp. 3224-3226
- Deswal, A.¹ Bozkurt, B.² Seta, Y.³ Parilti-Eiswirth, S.⁴ Hayes, F.A.⁵ Blosch, C.⁶ Mann, D.L.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.